← Human Trials & Peer-Reviewed Studies
Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02
Plain-language guide to PMID 18243498 (2008): randomized controlled trial study of Goserelin in 1995, men.
Key Facts
- PMID
- 18243498
- Journal
- European urology
- Year
- 2008
- Study type
- Randomized Controlled Trial
- Authors
- Efstathiou JA et al. (7 authors)
- DOI
- 10.1016/j.eururo.2008.01.021
- Registered trial
- NCT00767286
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Goserelin.
The researchers assessed the relationship between duration of GnRHa therapy and cardiovascular mortality in a large randomized trial of men treated with short-term versus longer-term adjuvant goserelin and radiation therapy (RT) for locally advanced prostate cancer.
Cox regression analyses were performed to evaluate the relationship between treatment arm and cardiovascular mortality.
Who Took Part
According to the abstract, 1995, men were involved.
PubMed indexes the participants as adults, middle-aged adults, older adults and people over 80, men only.
From 1992 to 1995, 1554 men with locally advanced prostate cancer (T2c-4, prostate-specific antigen [PSA] <150 ng/ml) received RT and 4 mo of goserelin and then were randomized to no additional therapy (arm 1) or 24 mo adjuvant goserelin (arm 2) in a phase 3 trial (Radiation Therapy Oncology Group [RTOG] 92-02).
How the Study Was Run
In design terms this was a randomized study.
Random assignment meant chance, not the researchers, decided who got Goserelin and who got the comparison, which limits bias.
Covariates included age, prevalent cardiovascular disease (CVD), hypertension, diabetes (DM), race, PSA, Gleason score, and stage.
What Was Measured
The subject headings attached to it are Antineoplastic Agents, Hormonal, Cardiovascular Diseases, Flutamide, Goserelin, Multivariate Analysis and Prostatic Neoplasms.
What This Means in Plain Language
The paper is a randomized study of Goserelin in 1995, men.
With several hundred people or more, it is a fairly large study for this kind of research.
The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2008 (European urology), a journal based in Switzerland.
More context: the Goserelin compound page.
Our Notes on the Compound
Goserelin: A GnRH analog implant (Zoladex) used to lower sex-hormone levels in prostate and breast cancer and gynecologic conditions.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.